# Latozinemab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/latozinemab

> Latozinemab, sponsored by Alector, Inc. (ALEC): 8 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | latozinemab |
| Codes | AL001 |
| Sponsor | Alector, Inc. (ALEC) https://sec-api.dev/companies/alec/catalysts |
| Indications | Neurodegenerative Diseases |
| Modality | antibody |
| FDA designations | breakthrough, fast track, orphan |

## Timeline

### Mar 2022: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-07-22, last confirmed 2025-07-22.
- SEC Form 10-K (accession 0001214659-25-010763): "We completed our Phase I clinical trial in March 2022 and initiated a Phase IIA Multiple Ascending Dose ("MAD") clinical trial in May 2022." https://www.sec.gov/Archives/edgar/data/1677077/000121465925010763/u7925110k.htm

### Mar 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-07-22, last confirmed 2026-07-22.
- SEC Form 10-K (accession 0001214659-26-008832): "We completed the Phase IIA clinical trial in March 2023, announced positive topline data in June 2023 and announced full data sets in October 2024." https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/az72426110k.htm
- SEC Form 10-K (accession 0001214659-26-008832): "We completed the Phase IIA clinical trial in March 2023 and announced positive topline data in June 2023." https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/az72426110k.htm
- SEC prospectus (424B) (accession 0001214659-26-002941): "We completed the Phase IIA clinical trial in March 2023, announced positive topline data in June 2023 and announced full data sets in October 2024." https://www.sec.gov/Archives/edgar/data/1677077/000121465926002941/i36260424b5.htm
- SEC prospectus (424B) (accession 0001214659-26-002941): "We completed the Phase IIA clinical trial in March 2023 and announced positive topline data in June 2023." https://www.sec.gov/Archives/edgar/data/1677077/000121465926002941/i36260424b5.htm
- SEC Form 10-Q (accession 0001214659-25-013609): "We completed the Phase IIA clinical trial in March 2023 and announced positive topline data in June 2023, followed by the full data set in October 2024." https://www.sec.gov/Archives/edgar/data/1677077/000121465925013609/u9325010q.htm
- SEC Form 10-K (accession 0001214659-25-010763): "We completed the Phase IIA clinical trial in March 2023, announced positive topline data in June 2023 and announced full data sets in October 2024." https://www.sec.gov/Archives/edgar/data/1677077/000121465925010763/u7925110k.htm

### Jul 2025: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2026-07-22, last confirmed 2026-07-22.
- SEC Form 10-K (accession 0001214659-26-008832): "In July 2025, the Company initiated its Phase II clinical trial of AL001 in patients with BD." https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/az72426110k.htm

### September 1, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Neurodegenerative Diseases.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06111014 (Continuation Study for Latozinemab): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-01 (ACTUAL); Lead Sponsor Alector Inc.." https://clinicaltrials.gov/study/NCT06111014

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2024-11-25, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-105023): "On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments" https://www.sec.gov/Archives/edgar/data/1653087/000095017025105023/alec-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-105023): "Alector and GSK remain on track to report topline data by the middle of the fourth quarter of 2025 from the pivotal, 96-week, randomized, double-blind, placebo-controlled INFRONT-3 Phase 3 trial evaluating latozinemab in frontotemporal dementia due to a GRN gene mutation (FTD-GRN)." https://www.sec.gov/Archives/edgar/data/1653087/000095017025105023/alec-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-066945): "Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025" https://www.sec.gov/Archives/edgar/data/1653087/000095017025066945/alec-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-066945): ""We remain on track to report topline results from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a granulin gene mutation in the fourth quarter of 2025, and we have completed enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 in early Alzheimer's disease." https://www.sec.gov/Archives/edgar/data/1653087/000095017025066945/alec-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-027734): "Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025" https://www.sec.gov/Archives/edgar/data/1653087/000095017025027734/alec-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-130564): "Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in frontotemporal dementia with a progranulin gene mutation is expected in late 2025 or early 2026." https://www.sec.gov/Archives/edgar/data/1653087/000095017024130564/alec-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-066945): "Alector and GSK remain on track to report topline data from the trial in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1653087/000095017025066945/alec-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-027734): "Topline data are anticipated by the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1653087/000095017025027734/alec-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-25-105050): "Topline data are anticipated from the trial by mid-fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1653087/000095017025105050/alec-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-066987): "Topline data are anticipated from the trial in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1653087/000095017025066987/alec-20250331.htm
- SEC Form 10-K (accession 0000950170-25-027758): "Topline data are anticipated from the trial by the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1653087/000095017025027758/alec-20241231.htm
- SEC Form 10-K (accession 0000950170-25-027758): "We anticipate topline data from INFRONT-3 by the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1653087/000095017025027758/alec-20241231.htm

### 1H 2026: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-10-21, last confirmed 2025-10-21.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-245102): "An independent interim analysis is planned for the first half of 2026." https://www.sec.gov/Archives/edgar/data/1653087/000119312525245102/alec-ex99_1.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-07-22, last confirmed 2026-09-10.
- SEC Form 10-Q (accession 0001214659-26-011572): "In March 2026, we announced the initiation of the Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with BD and expect to report topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1677077/000121465926011572/alz9226210q.htm
- SEC registration statement (S-1) (accession 0001214659-26-010726): "In March 2026, we announced the initiation of the Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with BD and expect to report topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1677077/000121465926010726/p820265s1.htm
- SEC Form 10-K (accession 0001214659-26-008832): "In March 2026, we announced the initiation of the Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with BD and expect to report topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/az72426110k.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-07-22, last confirmed 2026-09-10.
- SEC Form 10-Q (accession 0001214659-26-011572): "In March 2026, we announced the initiation of the Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with BD and expect to report topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1677077/000121465926011572/alz9226210q.htm
- SEC registration statement (S-1) (accession 0001214659-26-010726): "In March 2026, we announced the initiation of the Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with BD and expect to report topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1677077/000121465926010726/p820265s1.htm
- SEC Form 10-K (accession 0001214659-26-008832): "In March 2026, we announced the initiation of the Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with BD and expect to report topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/az72426110k.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/latozinemab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Latozinemab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/latozinemab

```bibtex
@misc{secapidev_pdufa_latozinemab_20261116,
  title        = {Latozinemab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/latozinemab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_latozinemab_20261116","title":"Latozinemab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/latozinemab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
